Tumor immunotherapy is a promising therapeutic strategy for patients with advanced
cancers. T cells are key mediators of antitumor function that specifically recognize and react …

In cancer, T cells become dysfunctional owing to persistent antigen exposure. Dysfunctional
T cells are characterized by reduced proliferative capacity, decreased effector function, and …

Therapeutic reinvigoration of tumor-specific T cells has greatly improved clinical outcome in
cancer. Nevertheless, many patients still do not achieve durable benefit. Recent evidence …

Recent progress in cancer immunotherapy emphasizes the importance of understanding
immune-regulatory pathways in tumours. Dysfunction of antitumour T cells may be due to …

Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

The immune system is capable of distinguishing between danger-and non-danger signals,
thus inducing either an appropriate immune response against pathogens and cancer or …

T-cell exhaustion was originally identified during chronic infection in mice, and was
subsequently observed in humans with cancer. The exhausted T cells in the tumor …

Immunotherapies have emerged as the most promising area in cancer treatments in recent
years. CD8+ T cells, as one of the primary effector cells of anticancer immunity, however …

The functional decline in T cells during their chronic stimulation, commonly referred to as T
cell exhaustion, is a major limitation for current immunotherapy approaches. As modern …

Immunotherapy plays an increasingly important role in the treatment of most malignant
tumors, and CD8+ T cells are the most important antitumor effector cells in the process of …